Constitutionality of new drug-pricing policy stirs debate

Amid an intensifying dispute over the ongoing new drug-pricing policy, a fresh debate over the constitutionality of so-called positive list system has arisen.

98 pharmaceutical firms of the Korea Pharmaceutical Manufacturers Association (KPMA) are seeking legal means to stop the law from going into effect, saying that the new system will fatally damage their earnings.

They claim the new ...